Buscar
Mostrando ítems 1-10 de 80
TLR4 deficiency upregulates TLR9 expression and enhances irinotecan-related intestinal mucositis and late-onset diarrhoea
(2021-10-01)
Background and purpose: Severe diarrhoea, a common gastrointestinal manifestation of anticancer treatment with irinotecan, might involve single nucleotide polymorphisms (SNPs) of toll-like receptors (TLRs), described as ...
The AI-discovered aetiology of COVID-19 and rationale of the irinotecan+ etoposide combination therapy for critically ill COVID-19 patients
We present the AI-discovered aetiology of COVID-19, based on a precise disease model of COVID-19 built under
five weeks that best matches the epidemiological characteristics, transmission dynamics, clinical features, ...
Involvement of nitric oxide on the pathogenesis of irinotecan-induced intestinal mucositis: role of cytokines on inducible nitric oxide synthase activation
(SPRINGERNEW YORK, 2012)
Purpose Intestinal mucositis and the closely associated diarrhea are common costly side effects of irinotecan. Cytokine modulators, such as thalidomide and pentoxifylline, are found capable of attenuating intestinal mucositis ...
Mitochondrial DNA as a Possible Ligand for TLR9 in Irinotecan-induced Small Intestinal Mucositis
(Informa Healthcare, 2022)
Mitochondrial DNA as a Possible Ligand for TLR9 in Irinotecan-induced Small Intestinal Mucositis
(Informa Healthcare, 2023)
The involvement of mast cells in the irinotecan-induced enteric neurons loss and reactive gliosis
(2017)
Abstract
Background
The irinotecan (CPT-11) causes intestinal mucositis and diarrhea that may be related to changes in the enteric nervous system (ENS). In inflammatory ...
Dictamen Preliminar de Evaluación de Tecnología Sanitaria N° 014-DETS-IETSI-2020. Eficacia y seguridad de panitumumab más folfiri para el tratamiento de pacientes adultos con cáncer colorrectal con gen KRAS no mutado que recibió terapia adyuvante con esquemas de oxaliplatino sin irinotecán y que progresa a metástasis, con ECOG 0-1
(Seguro Social de Salud (EsSalud), 2020-12)
En este documento se plasma la evaluación de la eficacia y seguridad del uso del producto farmacéutico panitumumab más FOLFIRI para el tratamiento de pacientes adultos con cáncer colorrectal con gen KRAS no mutado que ...